



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)
from Capital District Health Authority/*Cancer Care Nova Scotia***

**Guidelines for the Use of Degarelix in Advanced or Metastatic
Hormone Dependent Prostate Cancer**

Approved Use:

As a therapeutic option for testosterone suppression in patients with advanced or metastatic hormone dependant prostate cancer.

- This policy recommendation represents a **new guideline document** and a restriction of degarelix for patients with advanced or metastatic hormone dependant prostate cancer.